CGI Pharmaceuticals is a development stage pharmaceutical company that has leveraged its small molecule chemistry and kinase biology expertise to discover and develop an innovative pipeline of small molecule therapeutics a broad range of oncology and allergy/autoimmune/inflammatory disease (AAID) indications. CGI’s oncology drug development candidate, cgi1842, targets a unique combination of kinases that are critical for tumor anglogenesis. CGI was acquired by Gilead.
Tel: 203-315-1222 www.cellulargenomics.com
- CGI was acquired by Gilead.